Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting (Companion Faculty Lecture)

Featuring a slide presentation and related discussion from Prof Constantine Tam, including the following topics: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL): Results from the randomized CLL17 trial (0:00) Six-year follow-up data from the Phase III SEQUOIA trial of zanubrutinib for patients with treatment-naïve CLL and those with del(17p) CLL not randomly assigned (4:59) Primary endpoint analysis of the randomized STAIR trial of time-limited acalabrutinib monotherapy for frail patients with previously untreated CLL (7:25) Safety analyses of acalabrutinib/venetoclax (AV) or AV in combination with obinutuzumab for previously untreated CLL (10:50) Three-year results with zanubrutinib combined with venetoclax in arm D of the Phase III SEQUOIA trial for treatment-naïve CLL (17:15) Early-phase data with sonrotoclax combinations as front-line treatment of CLL (19:12) Pirtobrutinib for treatment-naïve and relapsed/refractory CLL/small lymphocytic lymphoma: Results from the Phase III BRUIN CLL-314 and BRUIN CLL-313 trials (23:27) Long-term extension (LTE1) results from the Phase III ALPINE trial of zanubrutinib versus ibrutinib in patients with relapsed/refractory CLL or small lymphocytic lymphoma (R/R CLL/SLL) (28:53) Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with R/R CLL/SLL from the ongoing phase 1 CaDAnCe-101 study (30:35) Real-world outcomes of lisocabtagene maraleucel in CLL (33:04) CME information and select publications